The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
Attention Deficit/Hyperactivity Disorder (ADHD) is a psychiatric disorder with an estimated global prevalence of 5.3% in children and adolescents. Diagnosis most commonly occurs in children, but the importance of identifying ADHD in the adult population has risen in the past decade. However, diagnosis remains difficult due to unknown genetic causes and a lack of accurate biomarkers.
The global ADHD Therapeutics market was valued at US$ 17430 million in 2023 and is anticipated to reach US$ 23430 million by 2030, witnessing a CAGR of 3.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for ADHD Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding ADHD Therapeutics.
Report Scope
The ADHD Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global ADHD Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Sale Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the ADHD Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Sale Channel, and by regions.
Market Segmentation
By Company
- Eli Lilly
- Novartis
- Takeda
- Pfizer
- GlaxoSmithKline
- Mallinckrodt Pharmaceuticals
- Hisamitsu Pharmaceutical
- Impax Laboratories
- Johnson & Johnson
- UCB S.A.
- Purdue Parma
Segment by Type
- Stimulants
- Non-stimulants
Segment by Sale Channel
- Specialty Clinics
- Hospital Pharmacies
- Retail Pharmacies
- E-Commerce
Consumption by Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Sale Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of ADHD Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Sale Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global ADHD Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Stimulants
1.2.3 Non-stimulants
1.3 Market by Sale Channel
1.3.1 Global ADHD Therapeutics Market Growth by Sale Channel: 2019 VS 2023 VS 2030
1.3.2 Specialty Clinics
1.3.3 Hospital Pharmacies
1.3.4 Retail Pharmacies
1.3.5 E-Commerce
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global ADHD Therapeutics Market Perspective (2019-2030)
2.2 ADHD Therapeutics Growth Trends by Region
2.2.1 Global ADHD Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 ADHD Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 ADHD Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 ADHD Therapeutics Market Dynamics
2.3.1 ADHD Therapeutics Industry Trends
2.3.2 ADHD Therapeutics Market Drivers
2.3.3 ADHD Therapeutics Market Challenges
2.3.4 ADHD Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top ADHD Therapeutics Players by Revenue
3.1.1 Global Top ADHD Therapeutics Players by Revenue (2019-2024)
3.1.2 Global ADHD Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global ADHD Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by ADHD Therapeutics Revenue
3.4 Global ADHD Therapeutics Market Concentration Ratio
3.4.1 Global ADHD Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by ADHD Therapeutics Revenue in 2023
3.5 ADHD Therapeutics Key Players Head office and Area Served
3.6 Key Players ADHD Therapeutics Product Solution and Service
3.7 Date of Enter into ADHD Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 ADHD Therapeutics Breakdown Data by Type
4.1 Global ADHD Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global ADHD Therapeutics Forecasted Market Size by Type (2025-2030)
5 ADHD Therapeutics Breakdown Data by Sale Channel
5.1 Global ADHD Therapeutics Historic Market Size by Sale Channel (2019-2024)
5.2 Global ADHD Therapeutics Forecasted Market Size by Sale Channel (2025-2030)
6 North America
6.1 North America ADHD Therapeutics Market Size (2019-2030)
6.2 North America ADHD Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America ADHD Therapeutics Market Size by Country (2019-2024)
6.4 North America ADHD Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe ADHD Therapeutics Market Size (2019-2030)
7.2 Europe ADHD Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe ADHD Therapeutics Market Size by Country (2019-2024)
7.4 Europe ADHD Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific ADHD Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific ADHD Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific ADHD Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific ADHD Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America ADHD Therapeutics Market Size (2019-2030)
9.2 Latin America ADHD Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America ADHD Therapeutics Market Size by Country (2019-2024)
9.4 Latin America ADHD Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa ADHD Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa ADHD Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa ADHD Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa ADHD Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly
11.1.1 Eli Lilly Company Detail
11.1.2 Eli Lilly Business Overview
11.1.3 Eli Lilly ADHD Therapeutics Introduction
11.1.4 Eli Lilly Revenue in ADHD Therapeutics Business (2019-2024)
11.1.5 Eli Lilly Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis ADHD Therapeutics Introduction
11.2.4 Novartis Revenue in ADHD Therapeutics Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Takeda
11.3.1 Takeda Company Detail
11.3.2 Takeda Business Overview
11.3.3 Takeda ADHD Therapeutics Introduction
11.3.4 Takeda Revenue in ADHD Therapeutics Business (2019-2024)
11.3.5 Takeda Recent Development
11.4 Pfizer
11.4.1 Pfizer Company Detail
11.4.2 Pfizer Business Overview
11.4.3 Pfizer ADHD Therapeutics Introduction
11.4.4 Pfizer Revenue in ADHD Therapeutics Business (2019-2024)
11.4.5 Pfizer Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline ADHD Therapeutics Introduction
11.5.4 GlaxoSmithKline Revenue in ADHD Therapeutics Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Mallinckrodt Pharmaceuticals
11.6.1 Mallinckrodt Pharmaceuticals Company Detail
11.6.2 Mallinckrodt Pharmaceuticals Business Overview
11.6.3 Mallinckrodt Pharmaceuticals ADHD Therapeutics Introduction
11.6.4 Mallinckrodt Pharmaceuticals Revenue in ADHD Therapeutics Business (2019-2024)
11.6.5 Mallinckrodt Pharmaceuticals Recent Development
11.7 Hisamitsu Pharmaceutical
11.7.1 Hisamitsu Pharmaceutical Company Detail
11.7.2 Hisamitsu Pharmaceutical Business Overview
11.7.3 Hisamitsu Pharmaceutical ADHD Therapeutics Introduction
11.7.4 Hisamitsu Pharmaceutical Revenue in ADHD Therapeutics Business (2019-2024)
11.7.5 Hisamitsu Pharmaceutical Recent Development
11.8 Impax Laboratories
11.8.1 Impax Laboratories Company Detail
11.8.2 Impax Laboratories Business Overview
11.8.3 Impax Laboratories ADHD Therapeutics Introduction
11.8.4 Impax Laboratories Revenue in ADHD Therapeutics Business (2019-2024)
11.8.5 Impax Laboratories Recent Development
11.9 Johnson & Johnson
11.9.1 Johnson & Johnson Company Detail
11.9.2 Johnson & Johnson Business Overview
11.9.3 Johnson & Johnson ADHD Therapeutics Introduction
11.9.4 Johnson & Johnson Revenue in ADHD Therapeutics Business (2019-2024)
11.9.5 Johnson & Johnson Recent Development
11.10 UCB S.A.
11.10.1 UCB S.A. Company Detail
11.10.2 UCB S.A. Business Overview
11.10.3 UCB S.A. ADHD Therapeutics Introduction
11.10.4 UCB S.A. Revenue in ADHD Therapeutics Business (2019-2024)
11.10.5 UCB S.A. Recent Development
11.11 Purdue Parma
11.11.1 Purdue Parma Company Detail
11.11.2 Purdue Parma Business Overview
11.11.3 Purdue Parma ADHD Therapeutics Introduction
11.11.4 Purdue Parma Revenue in ADHD Therapeutics Business (2019-2024)
11.11.5 Purdue Parma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
